Zydus Cadila approaches DCGI to use hepatitis drug for COVID-19 clinical trial
May 05, 2020
New Delhi [India], May 5 : The country's top drug regulator, Drug Controller General of India (DCGI), has received an application from Zydus Cadila, the leading global pharmaceutical company in India, to conduct clinical trial using antiviral drug 'Pegylated Interferon Alpha-2b' in adult COVID-19 patients.